Back to search

An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD

NCT03994328

NULLOBSERVATIONAL
Zambon SpA
1,235 participants
Started 2019-12-03 · Completed 2023-12-31
Status: Completed (as of 12-23-2025)

Conditions

Parkinson's Disease

Interventions

NULL

Linked Papers (from SciSciNet-V2)

Total Papers12
Background
1
Result
0
Derived
0
Unknown
11
View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

The purpose of this study is to evaluate how safinamide, rasagiline and other SoC drugs are associated with the quality of life of PD patients by means of the Parkinson's Disease Questionnaire (PDQ)-39 items.

Sort by:

Background Papers2

Retracted: Predictive Validity of a Medication Adherence Measure in an Outpatient Setting
2008
2,640 citations
Retracted: Predictive Validity of a Medication Adherence Measure in an Outpatient Setting
2008
2,640 citations

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers11

Parkinsonism
1967
11,463 citations
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
2009
1,586 citations
Validity of four pain intensity rating scales
2011
1,572 citations
Pharmacological Treatment of Parkinson Disease
2014
1,283 citations
Epidemiology and etiology of Parkinson’s disease: a review of the evidence
2011
1,134 citations
The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease
1995
1,086 citations
Levodopa‐induced dyskinesias
2007
440 citations
Guidelines for good pharmacoepidemiology practices (GPP)
2007
307 citations
Safinamide
2006
180 citations
Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
2013
137 citations
Using the PDQ-39 in routine care for Parkinson's disease
2018
26 citations